Streetbeat News

Stock Prices

JNJ

Johnson & Johnson's Phase 2 SKIPPirr study shows a significant reduction in infusion-related reactions for Rybrevant in lung cancer patients. The Phase 3 MARIPOSA study also highlights improved survival rates with Rybrevant plus Lazcluze compared to osimertinib. The FDA approved Rybrevant plus Lazcluze as a first-line therapy for EGFR-mutated NSCLC.

Portfolio Pulse from Vandana Singh

September 11, 2024 | 1:08 pm

FEMY

Femasys shares rise following the announcement of distribution partnerships for FemaSeed in Spain, valued at over $1.3 million.

Portfolio Pulse from Benzinga Newsdesk

September 11, 2024 | 1:07 pm

VRA

Vera Bradley's shares declined following disappointing Q2 financial results and a FY25 guidance that fell short of expectations.

Portfolio Pulse from Benzinga Newsdesk

September 11, 2024 | 1:06 pm

SHIBUSD

Shiba Inu's burn rate has spiked by 8,193%, but technical analysis suggests short-term weakness for the meme coin. Despite increased daily active addresses, large transactions have decreased, and a recent hack on Indodax resulted in the theft of 9 billion SHIB. SHIB is down 1.6% in the last 24 hours.

Portfolio Pulse from Khyathi Dalal

September 11, 2024 | 1:05 pm

PCT

PureCycle Technologies has raised $90 million through transactions with Sylebra Capital Management and Samlyn Capital. The funds will support the company's expansion in the recycled polypropylene market. The Ironton facility has achieved a significant processing milestone.

Portfolio Pulse from Benzinga Newsdesk

September 11, 2024 | 1:04 pm

AMD

NVDA

An Oracle executive has indicated that AMD is gaining traction in the AI chip market, which is currently dominated by Nvidia. This development could impact the competitive dynamics in the AI hardware sector.

Portfolio Pulse from Benzinga Newsdesk

September 11, 2024 | 1:03 pm

AIM

AIM ImmunoTech Inc. announced that the analysis of complete clinical data from the AMP-518 trial supports Ampligen's potential to treat moderate-to-severe Post-COVID fatigue. AIM plans a follow-up clinical trial targeting this condition.

Portfolio Pulse from Benzinga Newsdesk

September 11, 2024 | 1:01 pm

BIOX

Bioceres Crop Solutions (NASDAQ:BIOX) has received mixed analyst ratings over the past three months, with a recent average price target of $15.25, down from $21.00. Analysts have adjusted their ratings and price targets, reflecting changes in market conditions and company performance. Despite a decline in revenue growth, Bioceres shows strong profitability and financial health, but faces challenges with high debt levels.

Portfolio Pulse from Benzinga Insights

September 11, 2024 | 1:01 pm

ANF

Abercrombie & Fitch (NYSE:ANF) has been analyzed by 8 analysts, showing a range of opinions from bullish to bearish. Recent assessments indicate a slight decline in the average 12-month price target. Analysts have adjusted their ratings and price targets, reflecting their views on the company's performance. Abercrombie & Fitch has shown strong financial performance with impressive revenue growth, net margin, ROE, and ROA, while maintaining a prudent debt management strategy.

Portfolio Pulse from Benzinga Insights

September 11, 2024 | 1:00 pm

PACS

Analysts have varied ratings for PACS Group (NYSE:PACS), with a recent trend towards bullish sentiment. The average 12-month price target has increased by 17.37% to $40.14. Analysts have raised their ratings and price targets, reflecting positive market dynamics and company performance. Despite strong revenue growth, PACS Group faces challenges with profitability and financial leverage.

Portfolio Pulse from Benzinga Insights

September 11, 2024 | 1:00 pm